|
Addgene inc
crispr cas9 Crispr Cas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/CRISPR-SP-Cas9+reporter+(Plasmid+%2362733)/bio_rxiv__64898__2026__11__04__762546-269-7-27 Average 96 stars, based on 1 article reviews
crispr cas9 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Addgene inc
crispr cas9 plasmid pv1382 Crispr Cas9 Plasmid Pv1382, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/pV1382+(Plasmid+%23111436)/bio_rxiv__64898__2026__11__03__763959-245-1-9 Average 93 stars, based on 1 article reviews
crispr cas9 plasmid pv1382 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Addgene inc
crispr cas9 plasmid Crispr Cas9 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/CRISPR-SP-Cas9+reporter+(Plasmid+%2362733)/pm42976007-252-5-19 Average 96 stars, based on 1 article reviews
crispr cas9 plasmid - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
plasmid mix expressing crispr cas9 Plasmid Mix Expressing Crispr Cas9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/AIRE-1+CRISPR%2FCas9+KO+Plasmid/pmc13737429-43-12-22 Average 94 stars, based on 1 article reviews
plasmid mix expressing crispr cas9 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
muc16 knockout plasmid ![]() Muc16 Knockout Plasmid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/Mucin+16+CRISPR%2FCas9+KO+Plasmid/pmc13756213-353-9-12 Average 94 stars, based on 1 article reviews
muc16 knockout plasmid - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Addgene inc
crispr cas9 knockout cell lines ![]() Crispr Cas9 Knockout Cell Lines, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/lentiCRISPR+v2+(Plasmid+%2352961)/pmc13693651-166-3-10 Average 96 stars, based on 1 article reviews
crispr cas9 knockout cell lines - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Santa Cruz Biotechnology
cells ![]() Cells, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/DZIP3+CRISPR%2FCas9+KO+Plasmid/pm42907603-375-1-9 Average 94 stars, based on 1 article reviews
cells - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Addgene inc
crispr cas9 technology ![]() Crispr Cas9 Technology, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/lentiCRISPRv2+puro+(Plasmid+%2398290)/bio_rxiv__64898__2026__10__16__759525-186-4-8 Average 98 stars, based on 1 article reviews
crispr cas9 technology - by Bioz Stars,
2026-11
98/100 stars
|
Buy from Supplier |
|
Addgene inc
px458 gfp crispr cas9 vectors ![]() Px458 Gfp Crispr Cas9 Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/crispr+cas9+plasmids/pSpCas9(BB)-2A-Puro+(PX459)+V2%2E0+(Plasmid+%2362988)/pm42877069-424-17-25 Average 96 stars, based on 1 article reviews
px458 gfp crispr cas9 vectors - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
Journal: Cancer letters
Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
doi: 10.1016/j.canlet.2026.218927
Figure Lengend Snippet: KPC and KPC-MUC16 KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16 KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16 KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16 KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16 KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16 KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16 KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.
Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a
Techniques: Immunostaining, Analysis, RNA Sequencing, Inhibition
Journal: Cancer letters
Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
doi: 10.1016/j.canlet.2026.218927
Figure Lengend Snippet: A. Cytokine profile from tumor-conditioned media from T3M4 and T3M4-MUC16 KO cell lines; ELISA for CCL2 in tumor-conditioned media from B. T3M4 and T3M4-MUC16 KO and C. Capan-1 and Capan 1-MUC16 KO cells; RT-PCR for CCL2 and Serpin-E1 gene expression in D. KPC and KPC-MUC16 KO , E. T3M4 and T3M4-MUC16 KO , F. Capan-1 and Capan 1-MUC16 KO cells; Western blotting for p-AKT, total AKT, p-IKKα/β, IKKα, Serpin-E1, CCL2. GAPDH is used as a loading control in G. KPC and KPC-MUC16 KO and H. T3M4, T3M4-MUC16 KO , Capan-1 and Capan 1-MUC16 KO cells; Immunostaining for Serpin-E1 and representative histoscore graph, immunostaining for CCL2 and representative mean fluorescence intensity graph in I. GEMM and J. Orthotopic KPC and KPC-MUC16 KO mouse models; K. Chemotaxis of BMDMs towards control media (without cells) and KPC and KPC-MUC16 KO cells (n=5); L. Chemotaxis of BMDMs towards control media (without cells) (n=4), tumor-conditioned media from KPC and KPC-MUC16 KO cells, KPC conditioned media with CCL2, Serpin-E1 neutralization and dual neutralization (n=5). * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** p ≤ 0.0001
Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a
Techniques: Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Gene Expression, Western Blot, Control, Immunostaining, Fluorescence, Chemotaxis Assay, Neutralization, Positive Control
Journal: Cancer letters
Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
doi: 10.1016/j.canlet.2026.218927
Figure Lengend Snippet: A. Experimental design for in vitro tumor cell and macrophage (BMDM) coculture; Flow cytometry quantification for B. iNOS+ CD86+ and C. CD206+ Arg-1+ macrophages in the KPC and KPC-MUC16 KO coculture at two ratios (1:1 or 2:1, macrophage: cancer cell); D. Experimental design for in vitro tumor conditioned media (CM) treatment on and BMDMs; Flow cytometry quantification for E. iNOS+ CD86+ and F. CD206+ Arg-1+ macrophages in control (media only), KPC and KPC-MUC16 KO conditioned macrophages, RT-PCR on control (media only), KPC and KPC-MUC16 KO conditioned macrophages for G. Arginase-1, H. IL-10, I. CXCL13, J. CD274, K. CD206, L. IL-1β expression. p values < 0.05 considered statistically significant.
Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a
Techniques: Expressing, In Vitro, Flow Cytometry, Control, Reverse Transcription Polymerase Chain Reaction
Journal: Cancer letters
Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
doi: 10.1016/j.canlet.2026.218927
Figure Lengend Snippet: A. Experimental design for macrophage depletion using clodronate liposomes (and control neutral liposomes) in the orthotopic model. B. Tumor images upon euthanasia at day 21 post implantation for the following groups: KPC + control liposomes (n=5), KPC + clodronate liposomes (n=4), KPC-MUC16 KO + control liposomes (n=7), KPC-MUC16 KO + clodronate liposomes (n=6); Tumor C. Weight and D. Volume; E. H&E staining for tumor tissues from all groups (10x magnification); Staining and flow cytometry quantification for splenic macrophage populations – F. F4/80+ total macrophages, G. F4/80+ iNOS+ CD86+ M1-like macrophages, H. F4/80+ CD206+ M2-like macrophages, I. M1/M2 ratio, and intratumoral macrophage populations – J. F4/80+ total macrophages, K. F4/80+ iNOS+ CD86+ M1-like macrophages, L. F4/80+ CD206+ M2-like macrophages, M. M1/M2 ratio, in KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16 KO + control liposomes, KPC-MUC16 KO + clodronate liposomes tumor-bearing mice. p values < 0.05 considered statistically significant.
Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a
Techniques: Liposomes, Control, Staining, Flow Cytometry, Formalin-fixed Paraffin-Embedded
Journal: Cancer letters
Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
doi: 10.1016/j.canlet.2026.218927
Figure Lengend Snippet: Staining and flow cytometry for splenic T cell populations – A. CD3+ total T cells, B. CD3+ CD4+ helper T cells, C. CD3+ CD8+ cytotoxic T cells, D. CD3+ CD4+ FOXP3+ regulatory T cells, E. CD3+ CD4+ FOXP3+ CD25+ activated regulatory T cells; and intratumoral T cell populations – F. CD3+ total T cells, G. CD3+ CD4+ helper T cells, H. CD3+ CD8+ cytotoxic T cells, I. CD3+ CD4+ FOXP3+ regulatory T cells, J. CD3+ CD4+ FOXP3+ CD25+ activated regulatory T cells in KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16 KO + control liposomes, KPC-MUC16 KO + clodronate liposomes tumor-bearing mice. p values < 0.05 considered statistically significant.
Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a
Techniques: Staining, Flow Cytometry, Control, Liposomes
Journal: Cancer letters
Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer
doi: 10.1016/j.canlet.2026.218927
Figure Lengend Snippet: A. UMAP clustering of cell types in orthotopic tumors from KPC (n=2) and KPC-MUC16 KO (n=2). B. Population analysis depicting percentages of cell types in KPC and KPC-MUC16 KO tumors. C. Spatial distribution of cell types including epithelial cells, dendritic cells, fibroblasts, endothelial cells, macrophages, proliferating immune cells and B cells in a KPC (sample 4690) and a KPC-MUC16 KO (sample 4342) tumor. D. Arginase-1 spatial gene expression in a KPC (sample 4690) and a KPC-MUC16 KO (sample 4342) tumor. Ligand-Receptor interaction modeling in KPC tumors (n=2) shown using a E. Heatmap depicting number of interactions between different cell types, F. Specific Ligand-Receptor pairs involved in macrophage-to-target cell crosstalk, G. Specific Ligand-Receptor pairs involved in source cell type-to-macrophage crosstalk. Ligand-Receptor interaction modeling in KPC-MUC16 KO tumors (n=2) shown using a H. Heatmap depicting number of interactions between different cell types, I. Specific Ligand-Receptor pairs involved in macrophage-to-target cell crosstalk, J. Specific Ligand-Receptor pairs involved in source cell type-to-macrophage crosstalk.
Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a
Techniques: Spatial Transcriptomics, Activation Assay, Analysis, Gene Expression